Internal Medicine
| 6 min read
Researchers are moving beyond the male default as evidence reveals how sex influences disease, drug response, and clinical outcomes.
| 4 min read
A synthetic flavone restored vaginal tissue in a preclinical model, offering a potential nonsteroidal treatment for genitourinary syndrome of menopause.
Researchers are uncovering how hidden sources of variability throughout the experimental workflow can shape scientific outcomes.
| 6 min read
Long framed as a gynecological condition, PMOS is now understood as a multisystem disorder with metabolic, psychological, and cardiovascular consequences.
| 4 min read
Study demonstrates that computationally-designed miniproteins can modulate GPCR activity in native cellular environments, expanding access to a major drug target family.
| 6 min read
NAMs are increasingly used to de-risk preclinical development decisions, yet their broader impact on toxicology will depend on whether they are required or simply encouraged by regulators.
| 4 min read
New regulatory frameworks, shifting incentives, and pragmatic trial designs could finally move patient engagement from rhetoric to reality.
| 3 min read
As the field moves from fecal transplants toward defined bacterial consortia, the technical gaps in design, analytics, and co-cultivation are coming into sharper focus.
| 5 min read
Endometriosis is still largely managed with pain relief, hormones, and surgery, but a new precision peptide therapy seeks to directly target the underlying lesion biology.
| 6 min read
Despite growing regulatory acceptance, widespread adoption of NAMs depends on workflow integration, reproducibility, and perceived risk in industry decision-making.
| 4 min read
Real-time clinical trials, pharma deals, cancer found to be rising in young people, and more led the news this week.
| 6 min read
Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.
